Table 1.
Vaccine type | Average eosinophil infiltration score | reference |
---|---|---|
(A) SARS Vaccine | ||
Study 1 (Score scale: 0–4) Score based on percent eosinophils on histologic evaluation. 7–8 mice per group. 5 microscopy fields for each mouse lung were evaluated. | ||
Whole virus (DIV) | ~3 | Tseng et al., 2012[12] |
Spike protein | ~2 | |
Spike protein virus-like particle | >3 | |
Whole virus (DIV) with alum | ~2 | |
Spike protein with alum | ~1.5 | |
Spike protein virus-like particle with alum | >3 | |
PBS control | ~0 | |
Study 2 (Score scale: 0–3) Score for eosinophils as percent of infiltrating cells for each vaccine dosage group. N= 7–8 per group. 10 to 20 microscopy fields for each mouse lung were scored. Scoring: 0= ,5% of cells, 1= 5–10% of cells, 2= 10–20% of cells, 3= 20% of cells. | ||
Spike protein | ~1.5 | Tseng et al., 2012[12] |
Whole virus (DIV) | ~2.5 | |
Whole virus (BPV) | Not available | |
Spike protein with alum | ~1.5 | |
Whole virus (DIV) with alum | ~2.5 | |
Whole virus (BPV) with alum | ~2.5 | |
PBS control | 0 | |
(B) MERS Vaccine | ||
Study 1 (Score scale: 0–3) 0- no pathology, 1- mild, 2- moderate, and 3-severe. | ||
Alum alone | 0 | Agrawal et al., 2016[39] |
MF59-like adjuvant alone | 0 | |
Whole virus with alum | 2 | |
Whole virus with MF59-like adjuvant | 2 | |
Whole virus | 2 |
DIV: double-inactivated whole virus vaccine, BPV: Beta propiolactone-inactivated whole virus vaccine.